Menu

Texas Considers GM Mosquitoes

In an effort to prevent the spread of Zika virus, Harris County officials are in discussions with Oxitec to release insects engineered to produce short-lived offspring.

Mar 28, 2017
Kerry Grens

FLICKR, NIAIDHealth officials in Harris County, Texas, which includes the city of Houston, are weighing the possibility of deploying genetically modified mosquitoes to fend off Zika, the Houston Chronicle reported earlier this month (March 19). These male Aedes aegypti, developed by U.K.-based Oxitec, are designed so that their offspring die young, before they spread disease.

Oxitec has reported success in reducing mosquito populations in field sites in Brazil, Panama, and elsewhere. Yet, a proposal to introduce the insects in Florida was shot down by residents last year and the company is looking for another town in the state to the project.

“It looks like we’re going to do or plan to do some sort of trial initially to test out the system,” Deric Nimmo, principal scientist at Oxitec, told the Houston Chronicle.

“We’re not abandoning the tried-and-true” approaches to mosquito control, Harris County Precinct 4 Commissioner Jack Cagle told the newspaper. “We’re willing to see—What can we add to the tried-and-true that can make this better, especially considering that the tried-and-true has some flaws?” The county will begin sampling mosquitoes this spring to see if any have developed resistance to pesticides.

The US Food and Drug Administration approved the mosquitoes for release in Florida last year, but the Houston Chronicle reported that the Environmental Protection Agency may yet weigh in.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!